Hogan Lovells advises OncoResponse on closing of $50m senior secured loan
Washington, D.C., 18 February 2022 — Global law firm Hogan Lovells has advised OncoResponse, a clinical-stage biotech company advancing immunotherapies for the treatment of cancer patients, in the closing of a $50 million senior secured term loan. Proceeds from the transaction will be used for general working capital and to support clinical testing of the company’s lead drug OR2805, which is currently in clinical development.
“This transaction is an important step in helping OncoResponse fund our clinical studies and expand our drug pipeline. We are pleased to have the support of Hogan Lovells as we develop important new treatments for cancer," said Chris Russell, chief financial officer of OncoResponse.
Further details of the transaction can be found here.
The Hogan Lovells team was led by partners Edward "Ned" Purdon (Washington, D.C. and New York) and Andrew Strong (Houston) with assistance from senior associates Nick Griffin (Houston) and Brooke Shekhar (Washington, D.C.) and associate Jason Sloan (New York).
The deal is a key example of the broad range of capabilities offered by Hogan Lovells’ multi-disciplinary Emerging Companies practice, which provides businesses in the life sciences and health care industry, including biotechs, with a wide range of services throughout all phases of their life cycle from corporate formation to growth capital, including venture and non-dilutive financings, all the way through strategic exits.